AGL earnings call summary

Prepared Highlights

• Q3 2025 revenue of $1.44 billion, medical margin of negative $57 million, adjusted EBITDA of negative $91 million (prepared).
• Medicare Advantage membership at Q3 end: 503,000 (vs. 525,000 in Q3 2024); ACO REACH membership: 115,000 (vs. 132,000 in Q3 2024) (CFO).
• Full-year 2025 impact of lower-than-expected risk adjustment on medical margin estimated at ~$150 million; exited markets negatively impacted Q3 by $20 million (CFO).
• First-half 2025 medical cost trends developed at ~5.7%; Q3 recorded at a little over 6% (CFO).
• ACO REACH Q3 adjusted EBITDA of $18 million, ahead of expectations (CFO).
• Operating cost reduction initiatives expected to reduce costs by ~$30 million in 2026 (CEO, CFO).
• Enhanced data pipeline now covers ~80% of members with direct payer data feeds (CEO).
• Approximately 75% of agilon members expected to be in 4+ Star plans for 2026 payment year (up from 71%); consolidated average of 4.2 stars across markets (CEO).
• Heart failure pathway: new inpatient diagnosis rate reduced from 18% (2024) to 5% (2025) across MA population; 30-day readmission rates below 5% vs. national average of ~20% (CEO).
• Cash and marketable securities at Q3 end: $311 million; off-balance sheet cash held by ACO entities: $172 million (CFO).

Official Guidance (2025 Full Year)

• Medicare Advantage membership: 503,000–506,000; ACO model membership: 113,000–115,000 (CFO).
• Revenue: $5.81 billion–$5.83 billion (CFO).
• Medical margin: negative $5 million to $15 million (CFO).
• Adjusted EBITDA: negative $270 million to negative $245 million (CFO).
• Year-end cash: ~$310 million (including ~$65 million off-balance sheet in ACO entities) (CFO).
• 2026 medical margin jumping-off point: $135 million (CFO).

Mgmt Quotes

• "We believe 2026 is shaping up to be a strong stepping stone in our transformation." (CEO)
• "We are taking a very disciplined approach to contracting... we are prepared to take decisive action." (CEO)
• "We have reduced our headcount and streamlined our capital requirements... to gain greater operating leverage." (CEO)
• "We are very pleased with our strong ACO REACH performance during the quarter, including our final 2024 reconciliation." (CFO)
• "While our contracting for 2026 is not final, if we cannot come to appropriate economic terms in certain markets, we may not contract with specific payers." (CFO)

Prepared Metrics